Transcriptomic Profiling Predicts Multiple Pathways and Molecules Associated With the Metastatic Phenotype of Oral Cancer Cells.
CSF2.
NF-kB
Oral cancer
inflammation
metastasis
transcriptome
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
29
10
2020
revised:
25
11
2020
accepted:
04
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
21
8
2021
Statut:
ppublish
Résumé
Metastasis to cervical lymph nodes of oral squamous cell carcinoma (OSCC) leads to a poor prognosis. The present study aimed at investigating the pathways and molecules associated with OSCC metastasis. The transcriptome between HSC-3 cells and their highly metastatic subline, HSC-3-M3 cells, was examined using gene expression microarray. Gene enrichment analyses and Ingenuity Pathway Analysis were performed. Kaplan-Meier plot analysis using a publicly available dataset was conducted to assess whether candidate molecules are prognosticators. A total of 1,018 genes were differentially expressed, and the inflammatory pathway and NF-kB were predicted to be activated in HSC-3-M3 cells. CSF2 was suggested to be an indicator of poor prognosis in head and neck cancers. Inflammation and NF-kB may be involved in the metastasis of OSCC, and CSF2 is a promising diagnostic and therapeutic molecule. Moreover, HSC-3-M3 cells are a useful cell line model for studying OSCC progression.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Metastasis to cervical lymph nodes of oral squamous cell carcinoma (OSCC) leads to a poor prognosis. The present study aimed at investigating the pathways and molecules associated with OSCC metastasis.
MATERIALS AND METHODS
METHODS
The transcriptome between HSC-3 cells and their highly metastatic subline, HSC-3-M3 cells, was examined using gene expression microarray. Gene enrichment analyses and Ingenuity Pathway Analysis were performed. Kaplan-Meier plot analysis using a publicly available dataset was conducted to assess whether candidate molecules are prognosticators.
RESULTS
RESULTS
A total of 1,018 genes were differentially expressed, and the inflammatory pathway and NF-kB were predicted to be activated in HSC-3-M3 cells. CSF2 was suggested to be an indicator of poor prognosis in head and neck cancers.
CONCLUSION
CONCLUSIONS
Inflammation and NF-kB may be involved in the metastasis of OSCC, and CSF2 is a promising diagnostic and therapeutic molecule. Moreover, HSC-3-M3 cells are a useful cell line model for studying OSCC progression.
Identifiants
pubmed: 33419893
pii: 18/1/17
doi: 10.21873/cgp.20238
pmc: PMC7796819
doi:
Substances chimiques
Biomarkers, Tumor
0
NF-kappa B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-27Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Cancer Lett. 2013 Oct 10;339(2):270-8
pubmed: 23834814
J Biomed Sci. 2009 Nov 16;16:100
pubmed: 19917110
J Cancer. 2019 Jun 2;10(12):2720-2734
pubmed: 31258780
Mol Cancer Ther. 2019 Aug;18(8):1430-1438
pubmed: 31171582
Oral Oncol. 1998 Jul;34(4):253-6
pubmed: 9813718
Cancer Res. 2013 Jan 1;73(1):395-405
pubmed: 23108143
Oncogene. 1997 Jun 12;14(23):2845-55
pubmed: 9190901
Oncogene. 2016 Oct 6;35(40):5304-5316
pubmed: 27041563
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Int J Cancer. 1994 May 1;57(3):406-12
pubmed: 8169003
Int J Cancer. 1997 Feb 20;74(1):69-74
pubmed: 9036872
Oncoimmunology. 2014 Aug 03;3(8):e953418
pubmed: 25610743
Oral Oncol. 2018 Apr;79:71-77
pubmed: 29598953
Cancer Res. 2020 Mar 1;80(5):950-963
pubmed: 31900260
Front Immunol. 2019 Sep 04;10:2055
pubmed: 31552022
J Cancer. 2016 Mar 26;7(6):711-21
pubmed: 27076853
BMC Oral Health. 2020 Jan 29;20(1):24
pubmed: 31996191
Int J Oncol. 2012 Sep;41(3):885-92
pubmed: 22735610
J Biochem. 2018 Oct 1;164(4):257-264
pubmed: 29726955
Head Neck. 2016 Aug;38(8):1145-51
pubmed: 27018982
J Oral Pathol Med. 1989 Aug;18(7):391-5
pubmed: 2585303
J Clin Oncol. 2017 Nov 1;35(31):3601-3609
pubmed: 28880746
JNCI Cancer Spectr. 2019 Nov 12;3(4):pkz055
pubmed: 32337482
Biochem Biophys Res Commun. 2019 May 21;513(1):81-87
pubmed: 30935694
BMC Cancer. 2010 Aug 17;10:437
pubmed: 20716363
Oral Oncol. 2008 Oct;44(10):920-6
pubmed: 18282785
J Cancer Res Clin Oncol. 1996;122(4):243-8
pubmed: 8601578
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14536-41
pubmed: 19706540
Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):329-35
pubmed: 22990112
Blood. 2012 Apr 12;119(15):3383-93
pubmed: 22323450
Mol Hum Reprod. 2000 Jun;6(6):561-5
pubmed: 10825375
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Res. 2011 Mar 1;71(5):1680-9
pubmed: 21189327
Oral Oncol. 2017 Apr;67:146-152
pubmed: 28351569
Cancer Sci. 2016 May;107(5):666-73
pubmed: 26918517
Med Sci Monit Basic Res. 2017 Apr 07;23:141-149
pubmed: 28386055
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
FEBS Open Bio. 2013 Dec 30;4:96-104
pubmed: 24490130
Cancer Res. 2015 Jul 1;75(13):2629-40
pubmed: 25952647
Mol Oncol. 2017 Jan;11(1):5-27
pubmed: 28085224
Oncol Lett. 2018 Feb;15(2):1379-1388
pubmed: 29434828
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jul;124(1):16-23
pubmed: 28434836
Oncotarget. 2015 Dec 8;6(39):41837-55
pubmed: 26540630
Arthritis Res. 2002;4(3):157-64
pubmed: 12010565
Anticancer Res. 2020 Nov;40(11):6101-6113
pubmed: 33109548
Mol Cancer Res. 2015 May;13(5):828-38
pubmed: 25700553
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Exp Mol Med. 2016 Jul 01;48(7):e242
pubmed: 27364892
Head Neck. 2019 Jun;41(6):1777-1784
pubmed: 30694002